Logo

IDYA

IDEAYA Biosciences, Inc.

IDYA

IDEAYA Biosciences, Inc. • NASDAQ
$35.62 ▼ -0.72% (-0.26)
Market Cap $3.12 B
52w High $36.55
52w Low $13.45
Dividend Yield 0%
P/E -18.85
Volume 494.54K
Outstanding Shares 87.67M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $207.834M ▲ $98.352M ▲ $119.244M ▲ 57.375% ▲ $1.35 ▲ $120.274M ▲
Q2-2025 $0 $87.573M ▲ $-77.491M ▼ 0% $-0.88 ▼ $-76.258M ▼
Q1-2025 $0 ▼ $83.256M ▼ $-72.178M ▲ 0% ▲ $-0.82 ▲ $-71.045M ▲
Q4-2024 $7M ▲ $150.495M ▲ $-130.312M ▼ -1.862K% ▼ $-1.49 ▼ $-129.669M ▼
Q3-2024 $0 $65.881M $-51.821M 0% $-0.6 $-50.809M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $786.894M ▲ $1.185B ▲ $93.102M ▲ $1.092B ▲
Q2-2025 $669.738M ▼ $1.041B ▼ $81.617M ▲ $959.653M ▼
Q1-2025 $692.508M ▲ $1.101B ▼ $76.506M ▲ $1.024B ▼
Q4-2024 $676.319M ▼ $1.124B ▼ $64.944M ▲ $1.059B ▼
Q3-2024 $920.029M $1.24B $59.455M $1.18B

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $119.244M ▲ $142.214M ▲ $41.767M ▼ $301K ▼ $184.282M ▲ $142.172M ▲
Q2-2025 $-77.491M ▼ $-62.474M ▼ $45.918M ▼ $1.205M ▼ $-15.351M ▼ $-63.137M ▼
Q1-2025 $-72.178M ▲ $-60.342M ▲ $79.817M ▲ $26.143M ▲ $45.618M ▲ $-61.672M ▲
Q4-2024 $-130.312M ▼ $-121.655M ▼ $-197.109M ▼ $2.753M ▼ $-316.011M ▼ $-122.757M ▼
Q3-2024 $-51.821M $-49.234M $-20.036M $286.504M $217.234M $-49.691M

Revenue by Products

Product Q1-2023Q2-2023Q3-2023Q3-2025
Research and Development Services
Research and Development Services
 $0 ▲$0 ▲$0 ▲$140.00M ▲
Werner Helicase Program Research And Development Service
Werner Helicase Program Research And Development Service
 $10.00M ▲$0 ▼$0 ▲$0 ▲

Five-Year Company Overview

Income Statement

Income Statement IDEAYA looks like a classic clinical‑stage biotech on the income side. Revenue is negligible and hasn’t really taken off yet, which is normal for a company without approved products. Operating expenses have steadily risen as the pipeline has grown more advanced, and that has translated into larger operating losses and deeper net losses per share over time. In simple terms, the company is clearly prioritizing research and clinical development over near‑term profitability, and that shows up as a widening red ink trend in recent years.

Balance Sheet

Balance Sheet The balance sheet has expanded meaningfully, with total assets and shareholders’ equity growing over the past several years. Debt remains very low, so the capital structure is largely equity‑funded, which reduces financial leverage risk but dilutes existing shareholders over time. Cash on the historical balance sheets is modest relative to total assets, but the research notes a much stronger cash position more recently, suggesting that capital raises and partnerships have substantially bolstered liquidity. Overall, the balance sheet looks built to support long R&D timelines, with limited reliance on borrowing.

Cash Flow

Cash Flow Cash flow reflects a business in investment mode. Operating cash flow has been consistently negative, and free cash flow mirrors that pattern, indicating ongoing cash burn to fund trials and discovery work. Capital spending on physical assets is minimal, so most cash use is tied directly to people, studies, and science rather than buildings or equipment. The key question for cash flow is runway: based on the commentary, recent cash infusions appear to provide several years of funding, but the company still depends on external capital or future partnership payments until it can generate meaningful product revenue.

Competitive Edge

Competitive Edge IDEAYA occupies a differentiated niche in precision oncology with a heavy focus on synthetic lethality, an area where it has built deep expertise and proprietary platforms. Its pipeline includes several candidates that aim to be first‑in‑class or best‑in‑class, targeting genetically defined cancers that are not yet well served by existing drugs. Partnerships with large pharma companies add external validation, development support, and non‑dilutive funding, which strengthen its position. At the same time, oncology is a crowded and fast‑moving field, and IDEAYA faces competition from both other synthetic lethality players and broader cancer drug developers, with clinical and regulatory outcomes remaining the biggest swing factors.

Innovation and R&D

Innovation and R&D Innovation and R&D are the core of IDEAYA’s story. The company combines gene‑targeted biology, dual‑CRISPR screening, AI‑driven discovery, and a proprietary compound library to systematically identify and develop synthetic lethality targets. Lead programs like darovasertib, IDE397, and IDE161 are designed for genetically defined cancers and have already generated encouraging early clinical signals. Behind these, a growing next‑generation pipeline and discovery engine aim to keep new programs flowing. The upside is significant scientific differentiation; the risk is that success hinges on delivering positive trial results across a small number of key programs, where setbacks can materially alter the outlook.

Summary

IDEAYA is an early‑commercial, research‑heavy biotech whose financials and prospects are dominated by its R&D strategy rather than current earnings. The income statement shows rising losses as the company leans into development, while the balance sheet and external commentary point to a strengthened cash position and minimal debt, giving it room to pursue long and expensive trials. Cash burn is meaningful but appears manageable for now given the reported runway. Competitively, IDEAYA has carved out a strong position in synthetic lethality with differentiated science, notable pharma partnerships, and a pipeline with multiple potential catalysts over the next few years. The opportunity is tied to converting this scientific and partnership strength into approved therapies; the main risks stem from clinical, regulatory, and competitive uncertainty that is typical for a company at this stage in biotech.

NEWS

November 28, 2025 · 6:00 AM UTC

IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Read more

November 24, 2025 · 6:00 AM UTC

IDEAYA Biosciences to Participate in Upcoming December 2025 Investor Relations Events

Read more

November 4, 2025 · 6:00 AM UTC

IDEAYA Biosciences Reports Third Quarter 2025 Financial Results and Provides Business Update

Read more

October 31, 2025 · 6:00 AM UTC

IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Read more

October 27, 2025 · 6:00 AM UTC

IDEAYA Biosciences to Participate in Upcoming November 2025 Investor Relations Events

Read more